Company news
Oryzon Genomics SA news in 2023
Oryzon Genomics SA's news releases, calls and decks from 2023, newest first.
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
December 4, 2023
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
November 21, 2023
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)
November 7, 2023
ORYZON to Provide Corporate Progress Updates at Several Events in November
November 6, 2023
ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023
October 27, 2023
ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
October 10, 2023
ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies
October 3, 2023
ORYZON to Provide Corporate Progress Updates at Several Events in October
October 2, 2023
ORYZON to Give Updates on Corporate Progress in September
September 5, 2023
ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023
July 24, 2023
ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
June 27, 2023
Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
June 21, 2023
ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
May 30, 2023
ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting
May 17, 2023
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023
May 10, 2023
ORYZON to Give Updates on Corporate Progress in May-June
May 9, 2023
ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder
April 3, 2023
ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients
March 15, 2023
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022
February 17, 2023
Decks in 2023
- Shareholder Meeting (June 2023)
Shareholder meeting · 36 slides · Jun 26, 2023